Press coverage about Steadymed (NASDAQ:STDY) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Steadymed earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.2524721337635 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research firms recently issued reports on STDY. JMP Securities restated a “market perform” rating on shares of Steadymed in a report on Tuesday, May 1st. ValuEngine upgraded shares of Steadymed from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Steadymed traded up $0.02, reaching $4.73, on Friday, Marketbeat reports. 40,515 shares of the company’s stock were exchanged, compared to its average volume of 120,654. The firm has a market capitalization of $125.14 million, a PE ratio of -10.99 and a beta of 0.47. Steadymed has a 52 week low of $2.60 and a 52 week high of $6.45.
Steadymed (NASDAQ:STDY) last issued its earnings results on Tuesday, May 15th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.18). Steadymed had a negative return on equity of 68.96% and a negative net margin of 2,177.00%. sell-side analysts expect that Steadymed will post -0.76 EPS for the current year.
In other news, insider Jonathan Rigby sold 46,566 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $4.50, for a total value of $209,547.00. Following the completion of the transaction, the insider now directly owns 41,605 shares in the company, valued at $187,222.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David W. Nassif sold 10,001 shares of the firm’s stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $4.50, for a total transaction of $45,004.50. Following the completion of the transaction, the chief financial officer now owns 34,314 shares of the company’s stock, valued at $154,413. The disclosure for this sale can be found here. Insiders have sold 68,724 shares of company stock valued at $309,258 in the last quarter. Company insiders own 38.63% of the company’s stock.
Steadymed Company Profile
SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Steadymed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steadymed and related companies with MarketBeat.com's FREE daily email newsletter.